2. Academic Validation
  3. Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography

  • J Med Chem. 2025 Feb 27;68(4):4635-4649. doi: 10.1021/acs.jmedchem.4c02672.
Mengjing Ji 1 2 3 4,  Xiangwei Wang 1 2 3 4,  Cheng Liu 1 2 3 4,  Guang Ma 1 2 3 4,  Xin Lu 1 2 3 4,  Bin Zhu 1 2 3 4,  Simin He 1 2 3 4,  Jianping Zhang 1 2 3 4,  Xiaoping Xu 1 2 3 4,  Shaoli Song 1 2 3 4,  Zhongyi Yang 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • 3 Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
  • 4 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China.
PMID: 39945599 DOI: 10.1021/acs.jmedchem.4c02672
Abstract

This study developed a novel PET radiotracer to screen breast Cancer patients sensitive to CDK4/6 inhibitors, guiding personalized treatment. Two CDK4/6-targeting precursors were synthesized and evaluated in vitro and in vivo. Three breast Cancer cell lines─MCF-7, MDA-MB-231, and MDA-MB-468─were selected based on decreasing sensitivity to palbociclib. Compared to [68Ga]Ga-DOTA-Hexa-CDKi, [68Ga]Ga-DOTA-Bua-CDKi clearly identified cell lines with high sensitivity to palbociclib. PET/CT imaging showed significantly higher uptake of [68Ga]Ga-DOTA-Bua-CDKi (8.40 ± 0.85%ID/g) in MCF-7 tumors 60 min after tracer injection, with significant differences in tumor uptake among the three models (P < 0.05). Blocking assays demonstrated specific tumor uptake of [68Ga]Ga-DOTA-Bua-CDKi. Biosafety tests validated its safety as a diagnostic agent. [68Ga]Ga-DOTA-Bua-CDKi showed highly specific targeting of CDK4/6 and effective contrast imaging in tumor models. To our knowledge, [68Ga]Ga-DOTA-Bua-CDKi is one of the first radiotracers to assess CDK Inhibitor sensitivity, offering promise for evaluating patient responses to CDK4/6 inhibitors.

Figures
Products